TickerGuard
Buy Day today: Good (62) Broad market participation · no major macro event
GANX

Gain Therapeutics Inc

Healthcare · Biotechnology

1.80$ +3.2% vs. previous close Closing price · As of: Sep 17, 2026

Statements

Income Statement

All figures as a percentage of revenue in the same period.

Tick rows to compare them in a chart (up to 4)

Income Statement GANX
Line item 2018 2019 2020 2021 2022 2023 2024 2025
100.0% 100.0% 100.0% 100.0% 100.0% 100.0%
7,822.5% 4,342.1% 5,883.4% 145.7%
100.0% 100.0% 100.0% 100.0% 100.0% 100.0%
4,012.2% 3,840.7% 7,822.5% 4,342.1% 5,979.2% 20,878.2%
1,077.4% 1,344.2% 4,325.1% 4,137.7% 6,808.9% 19,550.0%
5,089.7% 5,184.9% 12,147.5% 8,479.8% 12,788.1% 40,428.3%
-4,989.7% -5,084.9% -12,047.5% -8,379.8% -12,688.1% -40,328.3%
254.6% 49.7% 655.6% 71.4% 176.6%
-5,316.9% -5,293.7% -12,369.0% -8,416.4% -12,488.8% -40,210.7%
47.5% 17.2% 18.6% 2.4% 66.4% 143.7%
-5,364.4% -5,310.9% -12,387.7% -8,418.9% -12,555.1% -40,354.3%
-4,986.1% -5,078.7% -12,014.3% -8,407.0% -12,443.0% -40,059.2%

Data as of: September 17, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?